Literature DB >> 1879378

Transforming growth factor beta 1: an autocrine regulator of adrenocortical steroidogenesis.

J J Feige1, C Cochet, C Savona, D L Shi, M Keramidas, G Defaye, E M Chambaz.   

Abstract

Transforming growth factor beta 1 (TGF beta 1) is a member of a large family of structurally related regulatory polypeptides which comprises both functionally similar (TGF beta 1, TGF beta 2, TGF beta 3, TGF beta 4 and TGF beta 5) and functionally distinct proteins. In the past few years, TGF beta 1 has emerged as a multifunctional protein. One of its remarkable properties is its capacity to negatively modulate the differentiated, steroidogenic adrenocortical functions. We present here a review of the results from our recent work related to the effects of TGF beta 1 on bovine adrenocortical cell (zona fasciculata-reticularis) functions. We identified the steroid 17 alpha-hydroxylase (P-450 17 alpha) biosynthetic enzyme and the angiotensin II receptor as major targets whose expression are negatively regulated by TGF beta 1 in these cells. We characterized TGF beta 1 receptors at the surface of adrenocortical cells (mainly type I and type III receptors) and observed that their number is increased under ACTH treatment. Furthermore, we could detect the presence of immunoreactive TGF beta 1 in the bovine adrenal cortex whereas it was undetectable in the adrenal medulla and in the capsule. We also observed that adrenocortical cells secrete TGF beta 1 under a latent form together with large amounts of alpha 2-macroglobulin, a protease inhibitor known to be implied in the latency of TGF beta in serum. Taken together, these observations led us to a working hypothesis, proposing TGF beta 1 as an autocrine and/or paracrine regulator of adrenocortical steroidogenic functions. This concept points out the physiological activation of the latent TGF beta 1 complex as the important limiting step controlling its action in the adrenal cortex.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1879378     DOI: 10.1080/07435809109027201

Source DB:  PubMed          Journal:  Endocr Res        ISSN: 0743-5800            Impact factor:   1.720


  4 in total

1.  Transforming growth factor beta2 induced pleurodesis is not inhibited by corticosteroids.

Authors:  Y C Lee; C J Devin; L R Teixeira; J T Rogers; P J Thompson; K B Lane; R W Light
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

Review 2.  Adrenocortical carcinoma: a clinician's update.

Authors:  Martin Fassnacht; Rossella Libé; Matthias Kroiss; Bruno Allolio
Journal:  Nat Rev Endocrinol       Date:  2011-03-08       Impact factor: 43.330

3.  Adropin Stimulates Proliferation and Inhibits Adrenocortical Steroidogenesis in the Human Adrenal Carcinoma (HAC15) Cell Line.

Authors:  Ewelina Stelcer; Paulina Milecka; Hanna Komarowska; Karol Jopek; Marianna Tyczewska; Marta Szyszka; Marta Lesniczak; Wiktoria Suchorska; Karlygash Bekova; Beata Szczepaniak; Marek Ruchala; Marek Karczewski; Tomasz Wierzbicki; Witold Szaflarski; Ludwik K Malendowicz; Marcin Rucinski
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-08       Impact factor: 5.555

4.  Vascular endothelial growth factor receptor inhibitor SU5416 suppresses lymphocyte generation and immune responses in mice by increasing plasma corticosterone.

Authors:  Jamison J Grailer; Douglas A Steeber
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.